Viking Therapeutics (VKTX) Liabilities and Shareholders Equity (2014 - 2026)

Viking Therapeutics has reported Liabilities and Shareholders Equity for 13 years, with the latest figure at $521.9 million in Q2 2026.

• Quarterly Liabilities and Shareholders Equity fell 36.96% year-over-year to $521.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.6 billion (down 26.99% YoY) and the FY2025 annual result came in at $715.7 million, down 21.2% from the prior year.
• Liabilities and Shareholders Equity slipped to $521.9 million in Q2 2026 per VKTX's latest filing, from $608.2 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $967.5 million in Q1 2024 and troughed at $150.9 million in Q1 2023.
• A 5-year average of $558.6 million and a median of $565.1 million in 2026 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity surged 541.19% in 2024, then plunged 36.96% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $168.5 million in 2022, then soared by 118.65% to $368.5 million in 2023, then surged by 146.5% to $908.3 million in 2024, then fell by 21.2% to $715.7 million in 2025, then declined by 27.08% to $521.9 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $521.9 million, $608.2 million, and $715.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.